Aptose Biosciences Faces Nasdaq Delisting Challenge
Company Announcements

Aptose Biosciences Faces Nasdaq Delisting Challenge

Aptose Biosciences (APS) has provided an announcement.

Aptose Biosciences Inc. has been notified by Nasdaq that their stock has not met the minimum bid price of $1.00 for 30 consecutive days, risking their continued listing. They have 180 days, until January 10, 2025, to comply by maintaining their bid price at or above $1.00 for at least 10 consecutive business days. While trading on the Nasdaq under “APTO” remains unaffected for now, they are also listed on the TSX under “APS,” which is not impacted by Nasdaq’s status. The company is exploring options to regain compliance but there is no guarantee of success.

Find detailed analytics on APS stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAptose Biosciences Reports Q3 2024 Financial Highlights
TipRanks Canadian Auto-Generated NewsdeskAptose Biosciences Advances AML Triplet Therapy
Christine BrownAPTO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App